Gedeon Richter Presents Scientific Posters from Psychiatric Congresses

Gedeon Richter Plc. has published scientific posters showcasing research findings on its pharmaceutical substances and their application in various psychiatric conditions. These materials stem from presentations at several European congresses focused on psychiatry and neuropsychiatry.

The research covers, among other areas, cariprazine's potential in treating schizophrenia, including its efficacy in late-stage disease, relapse prevention, and management of negative symptoms. One poster explores cariprazine use in female patients, while another addresses its role in managing dual disorders, which involve co-occurring psychiatric and substance use issues.

Furthermore, Gedeon Richter researchers presented posters examining cariprazine's safety profile within its approved dosage range. A separate publication analyzes the combination of cariprazine with clozapine, an atypical antipsychotic, for treatment-resistant schizophrenia. The company also shared data on cariprazine's application in the depressive phase of bipolar disorder.

The posters were presented at events such as the European Psychiatric Association (EPA) Annual Meeting, the European College of Neuropsychopharmacology (ECNP) Congress, and the World Psychiatric Association (WPA) World Congress, with publication dates ranging from late 2022 to early 2024. Gedeon Richter's research spans multiple therapeutic areas, including neuropsychiatry, women's healthcare, and general medicine.